Iyer Pritish, Moslim Maitham, Farma Jeffrey M, Denlinger Crystal S
Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA.
Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA.
Transl Gastroenterol Hepatol. 2020 Oct 5;5:52. doi: 10.21037/tgh.2020.01.02. eCollection 2020.
Diffuse gastric cancer (DGC) is a distinct histopathologic and molecular disease, characterized by mutations in CDH1, RHOA, and others. In addition, DGC is associated with familial syndromes, including hereditary DGC and germline mutation in CDH1. Clinically, this subtype of gastric adenocarcinoma is associated with a poor prognosis and possible resistance to available systemic therapies. An understanding of the genetic and molecular underpinnings of DGC may help inform of its clinical behavior and aid in screening, diagnosis, and response to treatment. In this review, we will review the current histologic, molecular, and genetic landscape of DGC and its relevance to clinical practice.
弥漫性胃癌（DGC）是一种独特的组织病理学和分子疾病，其特征在于CDH1、RHOA等基因发生突变。此外，DGC与家族性综合征相关，包括遗传性DGC和CDH1基因的种系突变。临床上，这种胃腺癌亚型预后较差，可能对现有的全身治疗产生耐药性。了解DGC的遗传和分子基础可能有助于了解其临床行为，并有助于筛查、诊断和治疗反应。在本综述中，我们将回顾DGC目前的组织学、分子和遗传学情况及其与临床实践的相关性。
